España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
UCB
UCBJF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$195.25
Last update: Dec 31, 7:00 PM
Get Report
Comment
UCB (UCBJF) Forecast
News
Earnings
UCB (UCBJF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for UCB (OTC:UCBJF) Stock
UCB Stock (OTC: UCBJF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 20, 2024
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Vandana Singh
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
Vandana Singh
Tuesday, September 24, 2024
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
Vandana Singh
Tuesday, September 10, 2024
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
Vandana Singh
Thursday, August 29, 2024
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Vandana Singh
Monday, August 26, 2024
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
Vandana Singh
Tuesday, January 02, 2024
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Vandana Singh
Thursday, September 28, 2023
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Vandana Singh
Thursday, August 31, 2023
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
Vandana Singh
Tuesday, June 27, 2023
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
Vandana Singh
Tuesday, February 14, 2023
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Vandana Singh
Monday, March 28, 2022
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
Vandana Singh
Tuesday, February 08, 2022
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
Vandana Singh
Friday, January 21, 2022
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
Vandana Singh
Wednesday, January 19, 2022
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Vandana Singh
Wednesday, August 25, 2021
UCB Gets EU Approval For Bimekizumab In Psoriasis
Vandana Singh
Thursday, October 10, 2019
Ra Pharma Stock Doubles On $2.5B Buyout Deal With Belgian Biopharma UCB
Shanthi Rexaline
Friday, July 13, 2018
Amgen, UCB Resubmit BLA for EVENITY to FDA
Benzinga
Sunday, July 16, 2017
Amgen, UCB Announce FDA Provides CRL for BLA for EVENITY
Benzinga
Sunday, April 02, 2017
Amgen, UCB Report New Data Examining The Option Of A Second Course Of Treatment With EVENITY at ENDO 2017
Benzinga
Thursday, January 19, 2017
Dermira Announces Final CIMZIA Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Benzinga
Friday, February 19, 2016
FDA Approves Briviact to Treat Partial Onset ...
Benzinga
Friday, May 15, 2015
The FDA's Authority Challenged By Mallinckrodt
Benzinga
Thursday, January 30, 2014
Biogen, UCB Annouince Agreements to Commercialize MS, Hemophilia Therapies in Asia
Benzinga
Wednesday, January 01, 2014
Amgen Announces Romosozumab Phase 2 Data Published In NEJM Show Significant Increases In Bone Mineral Density
Benzinga
Tuesday, January 25, 2011
Boost for VRX-GSK Epilepsy Drug - Analyst Blog
Benzinga
Earnings Preview: Abbott Labs - Analyst Blog
Benzinga
Wednesday, January 12, 2011
UCB's Progress On-Track - Analyst Blog
Benzinga
Wednesday, December 15, 2010
UCB Commences Patient Enrolment - Analyst Blog
Benzinga
